

AWARENESS AND KNOWLEDGE OF VIRAL HEPATITIS PREVENTION AND TRANSMISSION IN HEALTHCARE WORKERS

JAMIL MF¹, KHAN AMI^{*1}, YOUSAF N², KHAN HDA¹, MALIK K¹, YOUSAF S¹

¹Department of Community Medicine, Nishtar Medical College and University (NMU & H) Multan, Pakistan ²Department of Biochemistry, CIMS Multan, Pakistan *Corresponding author's email address: drkhan1224@yahoo.com

(Received, 17th October 2023, Revised 06th December 2023, Published 20th January 2024)

Abstract: The objective of this study was to evaluate the knowledge and awareness of healthcare workers about the prevention and transmission of hepatitis B virus. The study was conducted in Nishtar Medical Hospital, Multan, from January 2023 to September 2023 and included 300 healthcare workers, such as doctors and nurses. The participants were asked to fill out a 50question questionnaire designed to test their knowledge about hepatitis B. The questionnaire was in English, but assistance was provided if needed. The questions were related to the virus, behaviors, and medical practices when treating infected patients, and it took an average of 30 minutes to complete. The results showed that 74% of the healthcare workers knew the consequences and possible complications of acquiring HBV infection. Between 69% and 80% of the respondents answered correctly about the transmission routes. However, only 24% of the HCWs knew the age distribution of the infections and that neonates were at the highest risk of developing it through mother-to-child transmission. Respondents answered wrongly about transmission through food and cutlery with the infected (55%). Only half of the workers knew about disposing of needles and syringes correctly. The average knowledge score was 24 ± 5 with a median score of 24 (10-33). Respondents performed the worst when answering questions about CHB monitoring and treatment. In conclusion, this study found that the awareness and knowledge about hepatitis B prevention and transmission among healthcare workers in Pakistan is poor. Therefore, it is recommended to make training programs mandatory for professionals to improve disease management.

Keywords: Hepatitis B, Health Care Workers, Prevention, Transmission

Introduction

Hepatitis B is a viral liver infection that is transmitted through blood and other body fluids and can lead to liver cancer, cirrhosis, and early death. Currently, an average of 257 million people are suffering from hepatitis B infection globally (Razavi-Shearer et al., 2018). Three-quarters of the infected people belong to the Asian and African demographic due to a lack of education and vaccine awareness (Childs et al., 2018). A total of 42% of deaths caused by liver cancer were accounted for by hepatitis B infection (Maucort-Boulch et al., 2018).

Pakistan has a high incidence of Hep B virus, with almost 7-9 million carriers of the disease (Mehmood et al., 2020). It has been estimated that in six years, nearly 3.25% of the country's population will report positive for the virus (Samo et al., 2021). Half a million people die from hep B annually, and this rate is increasing every year. Although the vaccination for hepatitis B was introduced in 2009 in Pakistan, the number of infected patients and mortality rate of hep B and its related complications has increased since the last decade. Mother-to-child transmission of the virus has been reported as the leading cause of chronic hepatitis B; neonatal vaccination within 24 hours of birth is recommended to mitigate the risk of transmission.

No nationwide plan for the prevention and elimination of viral hepatitis has been carried out in Pakistan to date, which indicates negligence towards the healthcare sector. However, healthcare workers are essential in-patient counseling and raising awareness. We conducted this study to evaluate the awareness and knowledge of healthcare workers regarding the prevention and transmission of the Hepatitis B virus.

Methodology

A cross-sectional study was conducted in Nishtar Medical Hospital, Multan, from January 2023 to September 2023. A total of 300 healthcare workers, including doctors and nurses, were included in the study. All participants provided their informed consent for the study. Those workers who did not consent to participate were excluded. The hospital's ethical board approved the study design.

The study participants were asked to complete a questionnaire to test the healthcare workers' knowledge. The language of the questionnaire was English, but assistance was provided in case of difficulty in comprehension. The questionnaire included 50 questions and took an average of 30 minutes. The majority of the questions (42) inquired about knowledge regarding the hepatitis B virus, three questions assessed their behaviors, and five questions were regarding medical practices when treating a patient infected with hepatitis B.

All the data was analyzed by STATA 12. Mean \pm SD and median were used to express continuous data, and



percentage was used to express categorical data. A knowledge score was given to each participant depending upon correct answers in the questionnaire. Univariate linear regression analysis was done to evaluate the relationship between the hepatitis B virus and patients' demographics, prior experience with the disease, and healthcare workers' training on the virus's management and treatment. Variables with a probability of more than 0.25 were analyzed in the multivariate analysis. 95% CI and regression coefficients were employed to establish an association between independent variables and outcome. Statistical significance was denoted by a probability value of 0.05 or more.

Results

The study analyzed 300 questionnaire responses. Most of the population (65%) were women, and 80 (60%) participants were 25-45 years old. 220 (73.3%) had previously treated a chronic hepatitis B patient, and 66.6% of the population was vaccinated. Almost half of the respondents, 41.6%, had attended hepatitis B training in the last two years. The patients' characteristics are shown in Table I.

Table II shows the frequency of correct responses to questions asked regarding hepatitis B. 222 (74%) were aware of the consequences of acquiring HBV infection and were aware of possible complications. 69-80% of the respondents responded correctly about transmission routes. However, only 24% of HCWs knew the correct age distribution of the infections and that neonates are at the

highest risk of developing it through mother-to-child transmission. The majority of the correct answers were received when inquired about mother-to-child transmission (90%), unprotected sexual activity (85%), and transfusion (80%). Respondents answered wrongly about transmission through food and cutlery with the infected (69%), through sneezing and coughing (81%), prevention of infection by thorough cleaning (50%), and not sharing food and cutlery with the infected (55%). Only half of the workers knew about the correct disposal of needles and syringes.

A total of 183 (61%) wore gloves while injecting patients, and only 144 (48%) disposed of the needle correctly, which indicates a risk of needle stick injury in 52% of workers. 42% of workers reported non-availability or inadequate availability of newborn HBV vaccine. Only 22-27% of the workers were conscious of working with or sharing food with an infected patient (Table III).

The average knowledge score was 24 ± 5 with a median score of 24 (10-33). Respondents performed the worst when answering questions about CHB monitoring and treatment (Table IV).

Multivariate analysis revealed that physicians performed better than nurses and midwives. Not receiving hepatitis B training affected the knowledge score by 0.9 points. Age, sex, work experience, and department did not significantly affect the score. Similarly, being tested and vaccinated and having previous encounters with an infected were not related to increase knowledge scores (Table V).

Table I: Patients' demographics

	N (%)
Age	
< 25 years	51 (17%)
25-45 years	180 (60%)
45 years <	69 (23%)
Gender	
Men	105 (35%)
Women	195 (65%)
Profession	
Physician	150 (50%)
Nurse	75 (25%)
Midwives	75 (25%)
Department	
Pediatrics	78 (26%)
General medicine	75 (25%)
Internal medicine	57 (19%)
Obstetric	90 (30%)
Experience	
<5 years	90 (30%)
5-10 years	105 (35%)
Ten years or more	105 (35%)
Tested for HBV	245 (81.6%)
Hepatitis B vaccinated	200 (66.6%)
Encounter with a chronic HB patient	220 (73.3%)
HBV training within the last two years	125 (41.6%)

Table II: Correct responses regarding Hepatitis B prevalence, management, and prevention

Inquiry	Correct responses N (%)
HBV prevalence and risk	
Prevalence of Hepatitis B in Pakistan	123 (41%)
Citation: Jamil M.F. Khan A.M.I. Yousaf N. Khan H.D.A. Malik K. Yousaf S. (202	1) Awareness and knowledge of

Route of infection of HBV-infected117 (3%)Age distribution of infected72 (24%)Effect of chronic hepatitis B infection222 (74%)Transmission of Virus222 (74%)Through handshake264 (88%)Through bandshake264 (88%)Through solutions of variable scual activity255 (85%)Through solutions of variable scual activity255 (85%)Through solutions of variable scual activity207 (69%)Through solutions of variable scual activity207 (69%)Through solutions of variable scual activity or compromised people273 (91%)Disposing of variable scual activity or compromised people273 (91%)Disposing of variable scual activity or compromised people273 (91%)Oute of variable scual necelles276 (62%)Not sharing food or cutlery with the infected person165 (55%)Use of condom277 (89%)Administration of varcine recipients219 (73%)Administration of varcine to newborn267 (89%)Safety of HBV variable183 (61%)Intervention for neonate born to a CHB mother222 (24%)Use after clinical procedure for prevention of needle stick injury140 (5%)Discarding needles properly for prevention of needle stick injury150 (50%)Of the family and safter clinical procedure for prevention of needle stick injury141 (47%)UBS screening of CHB patients with no symptoms248 (85%)Of the family of CHB patients with no symptoms246 (82%)Of the family of CHB patients with no symptoms240 (82%) <t< th=""><th></th><th></th></t<>				
Age distribution of infected72 (24%)Effect of chronic hepatitis B infection222 (74%)Transmission of virus224 (48%)Through handshake264 (88%)Through protected sexual activity255 (85%)Through protected sexual activity255 (85%)Through solution of or cultery with an infected patient270 (90%)Through sharing food or cultery with an infected patient207 (69%)Prevention273 (91%)Objossing of used syringes and needles276 (92%)Not sharing food or cultery with the infected person150 (50%)Administration of vaccinate rocipients219 (73%)Disposing of used syringes and needles273 (91%)Disposing of used syringes and needles273 (91%)Immunization219 (73%)Administration of vaccinate rocipients219 (73%)Administration of vaccinate rocipients219 (73%)Administration for neenate born to a CHB mother222 (74%)Intervention for neonate born to a CHB mother222 (74%)Intervention for neonate born to a CHB mother222 (74%)Intervention generely for prevention of needle stick injury246 (82%)Discarding needles importly for prevention of needle stick injury141 (47%)IBV screening258 (86%)Of HV patients with no symptoms248 (81%)Of HW patients with no symptoms258 (86%)Of HW patients with no symptoms258 (86%)Of HW patients with no symptoms264 (83%)Performing alpha-fetoprotein test for liver cancer screening96 (32%)	Route of infection of HBV-infected	117 (39%)		
Fried of chronic hepatitis B infection222 (74%)Transmission of virus	Age distribution of infected	72 (24%)		
Transmission of virusThrough handshake264 (88%)Through protected sexual activity255 (85%)Through protected sexual activity256 (85%)Through specing or coughing243 (81%)Mother-to-child transmission270 (90%)Through sharing food or cutlery with an infected patient207 (90%)Prevention100 (50%)Administration of vaccination to immunity-compromised people273 (91%)Disposing of used syringes and needles276 (92%)Not sharing food or cutlery with the infected person165 (55%)Use of condom273 (91%)Immunization180 (55%)Identification of vaccine recipients219 (73%)Administration of vaccine to newborn267 (89%)Safety of HBV vaccine183 (61%)Intervention for neonate born to a CHB mother222 (74%)Intervention for neonate born to a CHB mother222 (74%)Intervention for neonate born to a CHB mother228 (86%)Of pregnant women with no symptoms258 (86%)Of Hef Sanity of CHB patients with no symptoms258 (86%)Of Hef Sanity of CHB patients with no symptoms270 (90%)Tests performed for CHB confirmation264 (88%)Test performing alpha-fetoprotein test for liver cancer screening96 (32%)Performing alpha-fetoprotein test for liver cancer screening96 (32%)Performing alpha-fetoprotein test for liver cancer screening78 (26%)Performing alpha-fetoprotein test for liver cancer screening78 (26%)Performing alpha-fetoprotein test for liver c	Effect of chronic hepatitis B infection	222 (74%)		
Through handshale264 (88%)Through blood transfusion255 (85%)Through blood transfusion243 (81%)Mother-to-child transfusion270 (90%)Through sharing food or cutlery with an infected patient270 (90%)Prevention150 (50%)Administration of vaccination to immunity-compromised people273 (91%)Disposing of used syrings and needles276 (92%)Not sharing food or cutlery with the infected person165 (55%)Use of condom273 (91%)Immunization219 (91%)Immunization219 (91%)Immunization219 (93%)Administration of vaccine recipients219 (73%)Administration of vaccine roewborn267 (89%)Safety of HBV vaccine183 (61%)Interction safety150 (50%)Washing hands after clinical procedure for prevention of needle stick injury246 (82%)Discarding needles property for prevention of needle stick injury150 (50%)Not discarding the needle immediately to prevent needle stick injury141 (47%)HBV corecing258 (86%)01 HIV patients with no symptomsOf the family of CHB patients with no symptoms270 (90%)Tests performed tor confirm HBV immunity111 (37%)HBV corecing96 (32%)Performing alpha-fetoprotein test for liver cancer screening96 (32%)Performing alpha-fetoprotein test for liver cancer screening78 (26%)Performing alpha-fetoprotein test for liver cancer screening78 (26%)Performing alpha-fetoprotein test for liver cancer scree	Transmission of virus			
Through upprotected sexual activity255 (85%)Through sneezing or coughing243 (81%)Mother-to-child transmission270 (09%)Prevention270 (09%)Through cleaning and cooking food150 (50%)Administration of vaccination to immunity-compromised people273 (91%)Disposing of used syringes and needles276 (02%)Not sharing food or cutlery with the infected person165 (55%)Use of condom273 (91%)Immunization273 (91%)Immunization267 (89%)Intervention of vaccinate neexipients219 (73%)Administration of vaccine recipients219 (73%)Administration of vaccine to newborn267 (89%)Safety of HBV vaccine183 (61%)Intervention for neonate born to a CHB mother222 (74%)Uscarding needles procedure for prevention of needle stick injury246 (82%)Discarding needles properly for prevention of needle stick injury150 (50%)Not discarding the needle immediately to prevent needle stick injury150 (50%)Not discarding the needle immediately to prevent needle stick injury248 (82%)Of pregnant women with no symptoms248 (81%)Of Hte Sanily of CHB patients with no symptoms248 (81%)Of the family of CHB patients with no symptoms248 (81%)Of the family of CHB patients for liver cancer screening96 (32%)Performing alpha-feotoprotein test for liver cancer screening76 (32%)Performing alpha-feotoprotein test for liver cancer screening78 (26%)Performing alpha-feotoprotein t	Through handshake	264 (88%)		
Through blood transfusion 264 (88%) Through snezzing or coughing 243 (81%) Mother-to-child transmission 270 (90%) Prevention 207 (69%) Prevention 273 (91%) Disposing of used syringes and needles 276 (92%) Not sharing food or cutlery with the infected person 150 (50%) Administration of vaccination to immunity-compromised people 273 (91%) Immunization 273 (91%) Immunization 219 (73%) Administration of vaccine recipients 219 (73%) Administration of vaccine recipients 219 (73%) Administration for neonate born to a CHB mother 222 (74%) Infection safety Washing hands after clinical procedure for prevention of needle stick injury 150 (50%) Not discarding the needle immediately to prevent needle stick injury 150 (50%) 160 (50%) Not discarding the needle immediately to prevent needle stick injury 150 (50%) 160 (50%) Not discarding the needle immediately to prevent needle stick injury 160 (50%) 160 (50%) Of pregnant women with no symptoms 258 (86%) 00 for family of CHB patients with no symptoms 258 (86%) 111 (37%) HBV sore	Through unprotected sexual activity	255 (85%)		
Through sneezing or coughing243 (81%)Mother-to-child transmission270 (69%)Prevention207 (69%)Prevention207 (69%)Mother-to-child transmission150 (50%)Administration of vaccination to immunity-compromised people273 (91%)Disposing of used syringes and needles276 (62%)Not sharing food or cutlery with the infected person165 (55%)Use of condom273 (91%)Immunization273 (91%)Immunization of vaccine recipients119 (73%)Administration of vaccine to newborn267 (89%)Safety of HBV vaccine183 (61%)Intervention for neonate born to a CHB mother222 (74%)Intervention for neonate born to a CHB mother220 (74%)Intervention for neonate born to a CHB mother222 (74%)Of pregnant women with no symptoms258 (86%)Of HIV patients with no symptoms244 (82%)Of the family of CHB patients with no symptoms270 (90%)Tests performed to confirmation264 (88%)Disconfired to confirmation264 (88%)Of the family of CHB patients for liver cancer screening96 (32%)Performing alpha-fetop	Through blood transfusion	264 (88%)		
Mother-to-child transmission 270 (90%) Through sharing food or cutlery with an infected patient 207 (69%) Prevention 1 Through cleaning and cooking food 150 (50%) Administration of vaccination to immunity-compromised people 273 (91%) Disposing of used syringes and needles 276 (92%) Not sharing food or cutlery with the infected person 165 (55%) Use of condom 273 (91%) Immunization 273 (91%) Addministration of vaccine to newborn 267 (89%) Safety of HBV vaccine 183 (61%) Intervention for neonate born to a CHB mother 222 (14%) Infection safety 1 Washing hands after clinical procedure for prevention of needle stick injury 150 (50%) Not discarding the needle immediately to prevent needle stick injury 150 (50%) Not discarding the needle immediately to prevention of 268 (86%) 000%) Of Pregnant women with no symptoms 248 (81%) Of HV patients with no symptoms 248 (88%) Of HE family of CHB patients with no symptoms 270 (90%) Tests performed for CHB patients with no symptoms 270 (90%) Tests performed for CHB patients with no sympto	Through sneezing or coughing	243 (81%)		
Through sharing food or cutlery with an infected patient 207 (69%) Prevention 150 (50%) Administration of vaccination to immunity-compromised people 273 (91%) Disposing of used syringes and needles 276 (92%) Not sharing food or cutlery with the infected person 165 (55%) Use of condom 273 (91%) Immunization 219 (73%) Identification of vaccine recipients 219 (73%) Administration of vaccine to newborn 267 (89%) Safety of HBV vaccine 183 (61%) Intervention for neonate born to a CHB mother 222 (74%) Intervention for neonate born to a CHB mother 222 (74%) Discarding needles properly for prevention of needle stick injury 150 (50%) Not discarding the needle immediately to prevent needle stick injury 150 (50%) Not discarding the needle immediately to prevent needle stick injury 150 (50%) Of Pregnant women with no symptoms 248 (88%) Of HV patients with no symptoms 243 (81%) Of the family of CHB patients with no symptoms 243 (81%) Of the family of CHB patients for liver cancer screening 96 (32%) Performing alpha-fetoprotein test for liver cancer screening 96 (32%)	Mother-to-child transmission	270 (90%)		
Prevention 150 (50%) Through cleaning and cooking food 150 (50%) Administration of vaccination to immunity-compromised people 273 (91%) Disposing of used syringes and needles 276 (92%) Not sharing food or cultery with the infected person 165 (55%) Use of condom 273 (91%) Immunization 273 (91%) Identification of vaccine recipients 219 (73%) Addministration of vaccine to newborn 267 (89%) Safety of HBV vaccine 183 (61%) Intervention for neonate born to a CHB mother 222 (74%) Infection safety 150 (50%) Washing hands after clinical procedure for prevention of needle stick injury 246 (82%) Discarding needles properly for prevention of needle stick injury 150 (50%) Not discarding the needle immediately to prevent needle stick injury 141 (47%) HBV screening 05 Of Pregnant women with no symptoms 258 (86%) Of HIV patients with no symptoms 258 (86%) Of HIV patients with no symptoms 270 (00%) Tests performed for CHB patients with o symptoms 270 (00%) Tests performed for CHB patients for liver cancer screening 96 (32	Through sharing food or cutlery with an infected patient	207 (69%)		
Through cleaning and cooking food150 (50%)Administration of vaccination to immunity-compromised people273 (91%)Disposing of used syringes and needles276 (92%)Not sharing food or cutlery with the infected person165 (55%)Use of condom273 (91%)Immunization273 (91%)Identification of vaccine recipients219 (73%)Administration of vaccine to newborn267 (89%)Safety of HBV vaccine183 (61%)Intervention for neonate born to a CHB mother222 (74%)Washing hands after clinical procedure for prevention of needle stick injury246 (82%)Discarding needles properly for prevention of needle stick injury150 (50%)Not discarding the needle immediately to prevent needle stick injury150 (50%)Of pregnant women with no symptoms258 (86%)Of Hthy Patients with no symptoms270 (90%)Tests performed for CHB confirmation264 (88%)Tests performed to confirm HBV immunity111 (37%)HBV soccing98 (32%)Performing alpha-fetoprotein test for liver cancer screening96 (32%)Performing alpha-fetoprotein test for liver cancer screening78 (26%)Performing	Prevention			
Administration of vaccination to immunity-compromised people273 (91%)Disposing of used syringes and needles276 (92%)Not sharing food or cutlery with the infected person165 (55%)Use of condom273 (91%)Immunization273 (91%)Immunization of vaccine recipients219 (73%)Addministration of vaccine recipients219 (73%)Safety of HBV vaccine183 (61%)Intervention for neonate born to a CHB mother222 (74%)Interton safety183 (61%)Washing hands after clinical procedure for prevention of needle stick injury246 (82%)Discarding needles properly for prevention of needle stick injury150 (50%)Not discarding the needle immediately to prevent needle stick injury141 (47%)HBV screening0Of pregnant women with no symptoms243 (81%)Of HLV patients with no symptoms243 (81%)Of the family of CHB patients with no symptoms243 (81%)Of the family of CHB patients with no symptoms244 (88%)Tests performed to confirm HBV immunity111 (37%)HBV monitoring96 (32%)Screening of CHB patients for liver cancer screening96 (32%)Performing alpha-fetoprotein test for liver cancer screening78 (26%)Performing alpha-fetoprotein test for liver cancer screening78 (26%)<	Through cleaning and cooking food	150 (50%)		
Disposing of used syringes and needles276 (92%)Not sharing food or cutlery with the infected person165 (55%)Use of condom273 (91%)Immunization733 (91%)Identification of vaccine recipients219 (73%)Administration of vaccine to newborn267 (89%)Safety of HBV vaccine183 (61%)Interction safety183 (61%)Washing hands after clinical procedure for prevention of needle stick injury246 (82%)Discarding needles properly for prevention of needle stick injury150 (50%)Not discarding the needle immediately to prevent needle stick injury150 (50%)Of pregnant women with no symptoms258 (86%)Of HIV patients with no symptoms243 (81%)Of the family of CHB patients with no symptoms270 (90%)Tests performed for CHB confirmation264 (88%)Tests performed for CHB onfirmation264 (88%)Tests performing alpha-fetoprotein test for liver cancer screening96 (32%)Performing alpha-fetoprotein test for liver cancer screening96 (32%)Performing AST test for liver cancer screening78 (26%)Performing alpha-fetoprotein test for liver damage monitoring78 (26%)Performing alpha-fetoprotein test for liver cancer screening78 (26%)Performing alpha-fetoprotein test for liver damage monitoring78 (26%)<	Administration of vaccination to immunity-compromised people	273 (91%)		
Not sharing food or cutlery with the infected person165 (55%)Use of condom273 (91%)Immunization273 (91%)Identification of vaccine recipients219 (73%)Administration of vaccine to newborn267 (89%)Safety of HBV vaccine183 (61%)Intervention for neonate born to a CHB mother222 (74%)Intervention for neonate born to a CHB mother222 (74%)Intervention for neonate born to a CHB mother222 (74%)Uses afting needles properly for prevention of needle stick injury150 (50%)Not discarding the needle immediately to prevent needle stick injury150 (50%)Of tregnant women with no symptoms258 (86%)Of HIV patients with no symptoms270 (90%)Tests performed to confirm HBV immunity111 (37%)HBV monitoring113 (37%)Screening of CHB patients for liver cancer screening39 (13%)Performing alpha-fetoprotein test for liver cancer screening96 (32%)Performing alpha-fetoprotein test for liver cancer screening78 (26%)Performing alpha-fetoprotein test for liver cancer screening78	Disposing of used syringes and needles	276 (92%)		
Use of condom273 (91%)Immunization219 (73%)Identification of vaccine recipients219 (73%)Administration of vaccine to newborn267 (89%)Safety of HBV vaccine183 (61%)Interction safety222 (74%)Washing hands after clinical procedure for prevention of needle stick injury246 (82%)Discarding needles properly for prevention of needle stick injury150 (50%)Not discarding the needle immediately to prevent needle stick injury150 (50%)Not discarding the needle immediately to prevent needle stick injury141 (47%)HBV screening0f the family of CHB patients with no symptoms258 (86%)Of the family of CHB patients with no symptoms270 (90%)Tests performed for CHB confirmation264 (88%)Tests performed for CHB confirmation264 (88%)Tests performed to confirm HBV immunity111 (37%)HBV monitoring39 (13%)Sereening of CHB patients with recurrer screening96 (32%)Performing alpha-fetoprotein test for liver cancer screening96 (32%)Performing adominal ultrasound for liver cancer screening78 (26%)Performing adominal ultrasound for liver cancer screening78 (26%)Performing AST test for liver damage monitoring73 (9%)Performing AST test for liver damage monitoring78 (26%)Performing adhoninal ultrasound for liver cancer screening78 (26%)Performing adhoninal ultrasound for liver cancer screening78 (26%)Performing AST test for liver damage monitoring76 (25%)Performing	Not sharing food or cutlery with the infected person	165 (55%)		
Immunization 219 (73%) Identification of vaccine recipients 219 (73%) Administration of vaccine to newborn 267 (89%) Safety Of HBV vaccine 183 (61%) Intervention for neonate born to a CHB mother 222 (74%) Infection safety 222 (74%) Washing hands after clinical procedure for prevention of needle stick injury 246 (82%) Discarding needles properly for prevention of needle stick injury 150 (50%) Not discarding the needle immediately to prevent needle stick injury 141 (47%) HBV screening 0 Of pregnant women with no symptoms 258 (86%) Of HLV patients with no symptoms 243 (81%) Of the family of CHB patients with no symptoms 270 (90%) Tests performed to confirm HBV immunity 111 (37%) HBV monitoring 55% Sereening of CHB patients for liver cancer screening 96 (32%) Performing alpha-fetoprotein test for liver cancer screening 96 (32%) Performing alpha-fetoprotein test for liver cancer screening 96 (32%) Performing alpha-fetoprotein test for liver cancer screening 78 (26%) Performing alpha-fetoprotein test for liver cancer screening 78 (26%)	Use of condom	273 (91%)		
Identification of vaccine recipients219 (73%)Administration of vaccine to newborn267 (89%)Safety of HBV vaccine183 (61%)Intervention for neonate born to a CHB mother222 (74%)Infection safety224 (82%)Washing hands after clinical procedure for prevention of needle stick injury150 (50%)Not discarding the needle immediately to prevent needle stick injury141 (47%)HBV screening0f pregnant women with no symptoms258 (86%)Of HIV patients with no symptoms243 (81%)Of the family of CHB patients with no symptoms244 (88%)Tests performed for CHB confirmation264 (88%)Tests performed to confirm HBV immunity111 (37%)HBV monitoring96 (32%)Performing alpha-fetoprotein test for liver cancer screening96 (32%)Performing alpha-fetoprotein test for liver cancer screening96 (32%)Performing alpha-fetoprotein test for liver cancer screening78 (26%)Performing alpha-fetoprotein test for liver damage monitoring138 (46%)Performing alpha-fetoprotein test for liver damage monitoring138 (46%)	Immunization			
Administration of vaccine to newborn267 (89%)Safety of HBV vaccine183 (61%)Intervention for neonate born to a CHB mother222 (74%)Infection safetyWashing hands after clinical procedure for prevention of needle stick injury246 (82%)Discarding needles properly for prevention of needle stick injury150 (50%)Not discarding the needle immediately to prevent needle stick injury141 (47%)HBV screeningOf pregnant women with no symptoms258 (86%)Of HIV patients with no symptoms243 (81%)Of the family of CHB patients with no symptoms270 (90%)Tests performed to confirm HBV immunity111 (37%)HBV monitoringScreening of CHB patients for liver cancer screening96 (32%)Performing alpha-fetoprotein test for liver cancer screening96 (32%)Performing abdominal ultrasound for liver cancer screening78 (26%)Performing alpha-fetoprotein test for liver cancer screening78 (26%)Performing AST test for liver cancer screening78 (26%)Performing alpha-fetoprotein test for liver cancer screening78 (26%)Performing AST test for liver damage monitoring78 (26%)Performing ABha-fetoprotein test for liver can	Identification of vaccine recipients	219 (73%)		
Safety of HBV vaccine183 (61%)Intervention for neonate born to a CHB mother222 (74%)Infection safety222 (74%)Washing hands after clinical procedure for prevention of needle stick injury246 (82%)Discarding needles properly for prevention of needle stick injury150 (50%)Not discarding the needle immediately to prevent needle stick injury141 (47%)HBV screening07 pregnant women with no symptoms258 (86%)Of HIV patients with no symptoms258 (86%)Of HIV patients with no symptoms270 (90%)Tests performed to confirm HBV immunity111 (37%)HBV monitoring111 (37%)Screening of CHB patients for liver cancer screening96 (32%)Performing alpha-fetoprotein test for liver cancer screening96 (32%)Performing abominal ultrasound for liver cancer screening78 (26%)Performing alpha-fetoprotein test for liver cancer screening78 (26%)Performing alpha-fetoprotein test for liver cancer screening78 (26%)Performing alpha-fetoprotein test for liver cancer screening78 (26%)Performing abdominal ultrasound for liver cancer screening78 (26%)Performing alpha-fetoprotein test for liver cancer screening78 (26%)Performing AST test for liver damage monitoring78 (26%)Performing ABM138 (46%)Performing Alpha-fetoprotein test for liver cancer screening78 (26%)Performing Alpha-fetoprotein test for liver cancer screening78 (26%)Performing ABM138 (46%)Performing ABM138 (46%)P	Administration of vaccine to newborn	267 (89%)		
Intervention for neonate born to a CHB mother222 (74%)Infection safety246 (82%)Washing hands after clinical procedure for prevention of needle stick injury150 (50%)Not discarding the needle immediately to prevent needle stick injury141 (47%)HBV screening0f pregnant women with no symptoms258 (86%)Of HIV patients with no symptoms243 (81%)Of the family of CHB patients with no symptoms243 (81%)Of the family of CHB confirmation264 (88%)Tests performed to confirm HBV immunity111 (37%)HBV monitoring500 (13%)Screening of CHB patients for liver cancer39 (13%)Performing alpha-fetoprotein test for liver cancer screening96 (32%)Performing alpha-fetoprotein test for liver cancer screening78 (26%)Performing alpha-fetoprotein test for liver damage monitoring78 (26%)Performing alpha-fetoprotein test for liver damage monitoring78 (26%)Performing alpha-fetoprotein test for liver cancer screening78 (26%)Performing alpha-fetoprotein test for liver cancer screening78 (26%)Performing alpha-fetoprotein test for liver damage monitoring78 (26%)Performing alpha-fetoprotein test for liver cancer screening78 (26%)Performing alpha-fetoprotein test for liver cancer screening78 (26%)Performing alpha-fetoprot	Safety of HBV vaccine	183 (61%)		
Infection safety246 (82%)Washing hands after clinical procedure for prevention of needle stick injury246 (82%)Discarding needles properly for prevention of needle stick injury150 (50%)Not discarding the needle immediately to prevent needle stick injury141 (47%)HBV screening0Of pregnant women with no symptoms258 (86%)Of HIV patients with no symptoms243 (81%)Of the family of CHB patients with no symptoms270 (90%)Tests performed for CHB confirmation264 (88%)Tests performed to confirm HBV immunity111 (37%)HBV monitoring9Screening of CHB patients for liver cancer39 (13%)Performing alpha-fetoprotein test for liver cancer screening96 (32%)Performing alban-foctoprotein test for liver cancer screening96 (32%)Performing abdominal ultrasound for liver cancer screening78 (26%)Performing alpha-fetoprotein test for liver cancer screening78 (26%)Performing alpha-fetoprotein test for liver cancer screening78 (26%)Performing abdominal ultrasound for liver cancer screening78 (26%)Performing alpha-fetoprotein test for liver damage monitoring78 (26%) <td>Intervention for neonate born to a CHB mother</td> <td>222 (74%)</td>	Intervention for neonate born to a CHB mother	222 (74%)		
Washing hands after clinical procedure for prevention of needle stick injury246 (82%)Discarding needles properly for prevention of needle stick injury150 (50%)Not discarding the needle immediately to prevent needle stick injury141 (47%)HBV screening258 (86%)Of pregnant women with no symptoms258 (86%)Of the family of CHB patients with no symptoms243 (81%)Of the family of CHB patients with no symptoms270 (90%)Tests performed for CHB confirmation264 (88%)Tests performed to confirm HBV immunity111 (37%)HBV monitoring111 (37%)Screening of CHB patients for liver cancer screening96 (32%)Performing alpha-fetoprotein test for liver cancer screening96 (32%)Performing albanine transaminase test for liver cancer screening78 (26%)Performing alpha-fetoprotein test for liver damage monitoring73 (25%)Performing alpha-fetoprotein test for liver damage monitoring78 (26%)Performing alpha-fetoprotein test for liver cancer screening78 (26%)Performing alpha-fetoprotein test for liver damage monitoring78 (26%)Performing alpha-fetoprotein test for liver damage monitoring78 (26%)Performing alpha-fetoprotein test for liver cancer screening78 (26%)Performing alpha-fetoprotein test for liver cancer screening78 (26%) <t< td=""><td>Infection safety</td><td></td></t<>	Infection safety			
Discarding needles properly for prevention of needle stick injury150 (50%)Not discarding the needle immediately to prevent needle stick injury141 (47%) HBV screening	Washing hands after clinical procedure for prevention of needle stick injury	246 (82%)		
Not discarding the needle immediately to prevent needle stick injury141 (47%)HBV screening141 (47%)Of pregnant women with no symptoms258 (86%)Of HIV patients with no symptoms243 (81%)Of the family of CHB patients with no symptoms270 (90%)Tests performed for CHB confirmation264 (88%)Tests performed to confirm HBV immunity111 (37%)HBV monitoring5Screening of CHB patients for liver cancer39 (13%)Performing alapha-fetoprotein test for liver cancer screening96 (32%)Performing abanine transaminase test for liver cancer screening96 (32%)Performing actinue transaminase test for liver cancer screening78 (26%)Performing alapha-fetoprotein test for liver damage monitoring78 (26%)Performing alapha-fetoprotein test for liver damage monitoring138 (46%)Performing alapha-fetoprotein test for liver damage monitoring78 (26%)Performing alabine transaminase test for liver cancer screening78 (26%)Performing alabine transaminase test for liver cancer screening78 (26%)Performing abdominal ultrasound for liver	Discarding needles properly for prevention of needle stick injury	150 (50%)		
HBV screeningOf pregnant women with no symptoms258 (86%)Of HIV patients with no symptoms243 (81%)Of the family of CHB patients with no symptoms270 (90%)Tests performed for CHB confirmation264 (88%)Tests performed to confirm HBV immunity111 (37%)HBV monitoring39 (13%)Screening of CHB patients for liver cancer screening165 (55%)Performing alpha-fetoprotein test for liver cancer screening96 (32%)Performing AST test for liver cancer screening96 (32%)Performing abdominal ultrasound for liver cancer screening78 (26%)Performing alpha-fetoprotein test for liver cancer screening78 (26%)Performing abdominal ultrasound for liver damage monitoring75 (25%)Performing alpha-fetoprotein test for liver damage monitoring78 (26%)Performing abanine transaminase test for liver cancer screening78 (26%)Performing abdominal ultrasound for liver cancer screening78 (26%)Performing abanine transaminase test for liver damage monitoring78 (26%)Performing abanine transaminase test for liver cancer screening78 (26%)Performing abdominal ultrasound for liver cancer screening78 (26%)Curing CHB183 (61%)Administration of antivirals to CHB patients60 (20%)Curing CHB183 (61%) <tr< td=""><td>Not discarding the needle immediately to prevent needle stick injury</td><td>141 (47%)</td></tr<>	Not discarding the needle immediately to prevent needle stick injury	141 (47%)		
Of pregnant women with no symptoms258 (86%)Of HIV patients with no symptoms243 (81%)Of the family of CHB patients with no symptoms270 (90%)Tests performed for CHB confirmation264 (88%)Tests performed to confirm HBV immunity111 (37%) HBV monitoring	HBV screening			
Of HUV patients with no symptoms243 (81%)Of HUV patients with no symptoms270 (90%)Tests performed for CHB confirmation264 (88%)Tests performed to confirm HBV immunity111 (37%)HBV monitoring39 (13%)Screening of CHB patients for liver cancer39 (13%)Performing alpha-fetoprotein test for liver cancer screening96 (32%)Performing AST test for liver cancer screening96 (32%)Performing abdominal ultrasound for liver cancer screening96 (32%)Performing alpha-fetoprotein test for liver cancer screening96 (32%)Performing abdominal ultrasound for liver cancer screening78 (26%)Performing alpha-fetoprotein test for liver cancer screening78 (26%)Performing alpha-fetoprotein test for liver damage monitoring75 (25%)Performing alpha-fetoprotein test for liver cancer screening78 (26%)Performing alpha-fetoprotein test for liver cancer screening78 (26%)Performing alpha-fetoprotein test for liver damage monitoring138 (46%)Performing alominal ultrasound for liver cancer screening78 (26%)Performing addominal ultrasound for liver cancer screening78 (26%)Treatment183 (61%)CHB symptoms39 (13%)Curing CHB183 (61%)Administration of antivirals to CHB patients60 (20%)Consequence of improper monitoring and treatment66 (22%)	Of pregnant women with no symptoms	258 (86%)		
Of the family of CHB patients with no symptoms270 (90%)Tests performed for CHB confirmation264 (88%)Tests performed to confirm HBV immunity111 (37%) HBV monitoring 5Screening of CHB patients for liver cancer39 (13%)Performing alpha-fetoprotein test for liver cancer screening165 (55%)Performing alanine transaminase test for liver cancer screening96 (32%)Performing AST test for liver cancer screening96 (32%)Performing abdominal ultrasound for liver cancer screening84 (28%)Performing alpha-fetoprotein test for liver cancer screening78 (26%)Performing alpha-fetoprotein test for liver damage monitoring75 (25%)Performing alpha-fetoprotein test for liver damage monitoring138 (46%)Performing AST test for liver damage monitoring78 (26%)Performing alpha-fetoprotein test for liver cancer screening78 (26%)Performing alpha-fetoprotein test for liver damage monitoring78 (26%)Performing alpha-fetoprotein test for liver damage monitoring78 (26%)Performing alpha-fetoprotein test for liver cancer screening78 (26%)Performing abdominal ultrasound for liver cancer screening78 (26%)TreatmentTreatmentCHB symptoms39 (13%)Curing CHB183 (61%)Administration of antivirals to CHB patients60 (20%)Consequence of improper monitoring and treatment66 (22%)	Of HIV patients with no symptoms	243 (81%)		
Tests performed for CHB confirmation264 (88%)Tests performed to confirm HBV immunity111 (37%) HBV monitoring 39 (13%)Screening of CHB patients for liver cancer39 (13%)Performing alpha-fetoprotein test for liver cancer screening165 (55%)Performing alanine transaminase test for liver cancer screening96 (32%)Performing AST test for liver cancer screening96 (32%)Performing abdominal ultrasound for liver cancer screening96 (32%)Performing carcinoembryonic antigen test for liver cancer screening78 (26%)Performing alpha-fetoprotein test for liver damage monitoring75 (25%)Performing AST test for liver damage monitoring138 (46%)Performing AST test for liver damage monitoring60 (20%)Performing abdominal ultrasound for liver cancer screening78 (26%)Chertor and a performing alpha-fetoprotein test for liver damage monitoring78 (26%)Performing alpha-fetoprotein test for liver damage monitoring60 (20%)Performing abdominal ultrasound for liver cancer screening78 (26%)TreatmentCHBCHB symptoms39 (13%)Curing CHB183 (61%)Administration of antivirals to CHB patients60 (20%)Consequence of improper monitoring and treatment66 (22%)	Of the family of CHB patients with no symptoms	270 (90%)		
Tests performed to confirm HBV immunity111 (37%)HBV monitoring	Tests performed for CHB confirmation	264 (88%)		
HBV monitoringScreening of CHB patients for liver cancer39 (13%)Performing alpha-fetoprotein test for liver cancer screening165 (55%)Performing alanine transaminase test for liver cancer screening96 (32%)Performing AST test for liver cancer screening96 (32%)Performing abdominal ultrasound for liver cancer screening84 (28%)Performing carcinoembryonic antigen test for liver cancer screening78 (26%)Performing alpha-fetoprotein test for liver damage monitoring75 (25%)Performing alanine transaminase test for liver damage monitoring138 (46%)Performing AST test for liver damage monitoring60 (20%)Performing abdominal ultrasound for liver cancer screening78 (26%)Performing alanine transaminase test for liver damage monitoring138 (46%)Performing AST test for liver damage monitoring60 (20%)Performing abdominal ultrasound for liver cancer screening78 (26%)TreatmentUltrasound for liver cancer screeningCHB symptoms39 (13%)Curing CHB183 (61%)Administration of antivirals to CHB patients60 (20%)Consequence of improper monitoring and treatment66 (22%)	Tests performed to confirm HBV immunity	111 (37%)		
Screening of CHB patients for liver cancer39 (13%)Performing alpha-fetoprotein test for liver cancer screening165 (55%)Performing alanine transaminase test for liver cancer screening96 (32%)Performing AST test for liver cancer screening96 (32%)Performing abdominal ultrasound for liver cancer screening96 (32%)Performing carcinoembryonic antigen test for liver cancer screening78 (26%)Performing alpha-fetoprotein test for liver damage monitoring75 (25%)Performing alanine transaminase test for liver damage monitoring138 (46%)Performing alanine transaminase test for liver cancer screening78 (26%)Performing alanine transaminase test for liver cancer screening78 (26%)Performing alanine transaminase test for liver damage monitoring138 (46%)Performing abdominal ultrasound for liver cancer screening78 (26%)Performing abdominal ultrasound for liver cancer screening78 (26%)TreatmentUCHB symptoms39 (13%)Curing CHB183 (61%)Administration of antivirals to CHB patients60 (20%)Consequence of improper monitoring and treatment66 (22%)	HBV monitoring			
Performing alpha-fetoprotein test for liver cancer screening165 (55%)Performing alanine transaminase test for liver cancer screening96 (32%)Performing AST test for liver cancer screening96 (32%)Performing abdominal ultrasound for liver cancer screening84 (28%)Performing carcinoembryonic antigen test for liver cancer screening78 (26%)Performing alpha-fetoprotein test for liver damage monitoring75 (25%)Performing alanine transaminase test for liver damage monitoring138 (46%)Performing AST test for liver damage monitoring60 (20%)Performing abdominal ultrasound for liver cancer screening78 (26%)Performing alpha-fetoprotein test for liver damage monitoring138 (46%)Performing alsoning test for liver damage monitoring60 (20%)Performing abdominal ultrasound for liver cancer screening78 (26%)CHB symptoms39 (13%)Curing CHB183 (61%)Administration of antivirals to CHB patients60 (20%)Consequence of improper monitoring and treatment66 (22%)	Screening of CHB patients for liver cancer	39 (13%)		
Performing alanine transaminase test for liver cancer screening96 (32%)Performing AST test for liver cancer screening96 (32%)Performing abdominal ultrasound for liver cancer screening96 (32%)Performing carcinoembryonic antigen test for liver cancer screening84 (28%)Performing alpha-fetoprotein test for liver damage monitoring78 (26%)Performing alanine transaminase test for liver damage monitoring138 (46%)Performing AST test for liver damage monitoring60 (20%)Performing abdominal ultrasound for liver cancer screening78 (26%)Performing abdominal ultrasound for liver cancer screening78 (26%)Performing abdominal ultrasound for liver cancer screening78 (26%)Performing abdominal ultrasound for liver cancer screening78 (26%)CHB symptoms39 (13%)Curing CHB183 (61%)Administration of antivirals to CHB patients60 (20%)Consequence of improper monitoring and treatment66 (22%)	Performing alpha-fetoprotein test for liver cancer screening	165 (55%)		
Performing AST test for liver cancer screening96 (32%)Performing abdominal ultrasound for liver cancer screening84 (28%)Performing carcinoembryonic antigen test for liver cancer screening78 (26%)Performing alpha-fetoprotein test for liver damage monitoring75 (25%)Performing alanine transaminase test for liver damage monitoring138 (46%)Performing AST test for liver damage monitoring60 (20%)Performing abdominal ultrasound for liver cancer screening78 (26%)Treatment78 (26%)CHB symptoms39 (13%)Curing CHB183 (61%)Administration of antivirals to CHB patients60 (20%)Consequence of improper monitoring and treatment66 (22%)	Performing alanine transaminase test for liver cancer screening	96 (32%)		
Performing abdominal ultrasound for liver cancer screening84 (28%)Performing carcinoembryonic antigen test for liver cancer screening78 (26%)Performing alpha-fetoprotein test for liver damage monitoring75 (25%)Performing alanine transaminase test for liver damage monitoring138 (46%)Performing AST test for liver damage monitoring60 (20%)Performing abdominal ultrasound for liver cancer screening78 (26%)Treatment78 (26%)CHB symptoms39 (13%)Curing CHB183 (61%)Administration of antivirals to CHB patients60 (20%)Consequence of improper monitoring and treatment66 (22%)	Performing AST test for liver cancer screening	96 (32%)		
Performing carcinoembryonic antigen test for liver cancer screening78 (26%)Performing alpha-fetoprotein test for liver damage monitoring75 (25%)Performing alanine transaminase test for liver damage monitoring138 (46%)Performing AST test for liver damage monitoring60 (20%)Performing abdominal ultrasound for liver cancer screening78 (26%)TreatmentCHB symptomsCuring CHBAdministration of antivirals to CHB patients60 (20%)Consequence of improper monitoring and treatment	Performing abdominal ultrasound for liver cancer screening	84 (28%)		
Performing alpha-fetoprotein test for liver damage monitoring75 (25%)Performing alanine transaminase test for liver damage monitoring138 (46%)Performing AST test for liver damage monitoring60 (20%)Performing abdominal ultrasound for liver cancer screening78 (26%)TreatmentCHB symptomsCuring CHBAdministration of antivirals to CHB patients60 (20%)Consequence of improper monitoring and treatment	Performing carcinoembryonic antigen test for liver cancer screening	78 (26%)		
Performing alarine transaminase test for liver damage monitoring138 (46%)Performing AST test for liver damage monitoring60 (20%)Performing abdominal ultrasound for liver cancer screening78 (26%)TreatmentCHB symptomsOutputCHB symptomsOutputCuring CHBAdministration of antivirals to CHB patients60 (20%)Consequence of improper monitoring and treatmentConsequence of improper monitoring and treatment	Performing alpha-fetoprotein test for liver damage monitoring	75 (25%)		
Performing AST test for liver damage monitoring60 (20%)Performing abdominal ultrasound for liver cancer screening78 (26%)Treatment39 (13%)CHB symptoms39 (13%)Curing CHB183 (61%)Administration of antivirals to CHB patients60 (20%)Consequence of improper monitoring and treatment66 (22%)	Performing alanine transaminase test for liver damage monitoring	138 (46%)		
Performing abdominal ultrasound for liver cancer screening78 (26%)Treatment39 (13%)CHB symptoms39 (13%)Curing CHB183 (61%)Administration of antivirals to CHB patients60 (20%)Consequence of improper monitoring and treatment66 (22%)	Performing AST test for liver damage monitoring	60 (20%)		
TreatmentCHB symptoms39 (13%)Curing CHB183 (61%)Administration of antivirals to CHB patients60 (20%)Consequence of improper monitoring and treatment66 (22%)	Performing abdominal ultrasound for liver cancer screening	78 (26%)		
CHB symptoms39 (13%)Curing CHB183 (61%)Administration of antivirals to CHB patients60 (20%)Consequence of improper monitoring and treatment66 (22%)	Treatment			
Curing CHB183 (61%)Administration of antivirals to CHB patients60 (20%)Consequence of improper monitoring and treatment66 (22%)	CHB symptoms	39 (13%)		
Administration of antivirals to CHB patients60 (20%)Consequence of improper monitoring and treatment66 (22%)	Curing CHB	183 (61%)		
Consequence of improper monitoring and treatment 66 (22%)	Administration of antivirals to CHB patients	60 (20%)		
	Consequence of improper monitoring and treatment	66 (22%)		

Table III: Medical practices of healthcare workers

	N (%)
Availability of newborn HBV vaccination	174 (58%)
Use of gloves while injecting patients	183 (61%)
Correct disposal of needles after injecting patients	144 (48%)
Needle stick injury in the last 12 months	72 (24%)
Availability of sharp-proof containers for disposing of syringes and needles	246 (82%)
Concerned with working with a CHB patient	81 (27%)
Concerned with sharing food with CHB patients	66 (22%)

Table IV: HBV knowledge score

	Average score	Median score
Prevalence and risk	2.1 ± 0.9	2 (0-4)
Transmission	4.8 ± 1.5	5 (0-6)
Prevention	4.0 ± 1.3	4 (0-5)
Immunization	2.8 ± 0.9	3 (0-4)
Injection safety	2.0 ± 1.0	2 (0-3)
Testing	3.8 ± 1.5	4 (0-5)
CHB monitoring	2.9 ± 2.4	3 (0-8)
CHB treatment	1.6 ± 1.0	1 (0-4)
Total score	24 ± 5	24 (10-33)

Table V: Factors Influencing Knowledge Score

	Univariate analysis		Multivariate analysis			
	Coefficient	t	р	Adjusted coefficient	95% CI	р
Age						
Younger than 25 years	Reference	-	-	Reference	-	-
25-34 years	1.9	2.3	0.04	0.3	-2.0 to 2.2	0.90
35-45 years	1.8	2.2	0.05	-0.3	-2.8 to 2.6	0.90
Older than 45 years	1.20	1.5	0.20	-0.5	-3.0 to 2.5	0.79
Gender						
Men	Reference	-	-	Reference	-	-
Women	-0.4	-0.6	0.69			
Profession						
Physician	Reference	-	-	Reference	-	-
Nurse	-4.6	-3.8	< 0.001	-4.8	-8.0 to 2.0	0.001
Midwives	-3.1	-4.1	< 0.001	-3.2	-4.7 to -1.7	< 0.001
Department						
Internal medicine	Reference	-	-	Reference	-	-
General medicine	-1.3	-1.5	0.20	-0.8	-2.6 to 1.5	0.50
Pediatrics	-0.5	-0.5	0.70	-0.8	-2.7 to 1.6	0.49
Obstetric	-1.1	-1.3	0.29	0.5	-1.7 to 2.2	0.80
Experience						
Less than five years	Reference	-	-	Reference	-	-
5-10 years	1.0	1.5	0.19	0.6	-0.8 to 1.5	0.58
Ten years or more	0.5	0.6	0.68	-0.08	-2.0 to 1.9	0.90
Not tested for HBV	-1.5	-2.0	0.10	-0.8	-2.5 to 0.5	0.09
Not hepatitis B	-0.8	-2.1	0.70			
vaccinated						
No encounter with a	-1.8	-3.0	0.008	-0.9	-2.5 to 0.8	0.059
chronic HBI patient						
No HBV training within	-0.8	-1.8	0.05	-0.9	-1.9 to -0.2	0.030
the last two years						

Discussion

Hepatitis B infection is a frequent and contagious condition in Pakistan. With the increasing incidence of HBV, health professionals need to be educated about the management and prevention of the disease. We conducted this study to assess healthcare workers' knowledge regarding the prevention and transmission of hepatitis B. However, the results revealed disappointing results. Out of 50, the average score was 24.

The professionals were not aware of the HBV prevalence (41%) and the primary cause of it being mother-to-child transmission (24%). 42% of respondents wrongly believed

the direct transmission of CHB was through sexual activity. Only 24% knew about the high risk of CHB to the neonate. 69% thought the transmission was through sharing food and cutlery with the infected. The lack of awareness regarding the transmission of the disease may be a reason for the increased risk of CHB in neonates. Similar results were reported by other studies conducted among healthcare workers in Pakistan (Butt and Ahmed, 2018; Khan et al., 2019; Soomar et al., 2021).

Since mother-to-child transmission of chronic hepatitis B is high, it is essential to administer vaccination to the newborn at birth to prevent infection. Professionals handle 98% of births. Hence, they are responsible for the safety of infants

against disease. Our study revealed the lack of knowledge of healthcare workers regarding the vaccine. Only 61% of workers could confirm the safety of the Hep B vaccine. This skepticism has also been noted in the general public, which is why most of the population is unvaccinated. However, in a study conducted in Punjab, pregnant mothers were aware and confident of the vaccination after female health workers and birth attendants gave information (Gul et al., 2022; Maqsood et al., 2021). The lack of acceptance of the hep B vaccine among healthcare workers may be due to wrong beliefs, attitudes, and practices at their institute (Akazong et al., 2020; Mursy and Mohamed, 2019; Qin et al., 2018). However, this behavior puts the infants at high risk of infection. Therefore, more research is needed to investigate these attitudes.

Not only the patients but healthcare workers are also at high risk of acquiring hep B infection, with the risk being multiplied by fourfold than for an average person (Shao et al., 2018). WHO reported a 5.9% prevalence of HBV among healthcare workers every year around the world (Prüss-Üstün et al., 2005). Although this frequency is lower in Pakistan, given the HBV antigen is 2.5%, this risk increases every year (Waheed et al., 2019). As noted in our study, the workers are at higher risk due to a lack of proper knowledge and employing necessary precautions for prevention. Poor vaccination coverage for health professionals and globally also contributes to that (Auta et al., 2018). In our study, 66.6% were vaccinated, which is consistent with other studies (Abidi et al., 2018; Basireddy et al., 2018). Compliance with injection safety protocols was also poor (48%), which is higher than reported in the literature (Musroor and Saleem, 2020) 61% reported wearing gloves while injection patients and 24% reported a needle stick injury in the last year, which is significantly lower than other studies (Abbas et al., 2023).

The lowest knowledge score was among the questions regarding CHB monitoring and treatment. Only 1-2% of the respondents could answer correctly to all questions about testing and screening for liver cancer and damage. Therefore, there is a need for frequent and mandatory CHB training for healthcare professionals to improve disease management and prevention.

Another factor worth mentioning is the lower scores of nurses and midwives than physicians. A strong association between the profession of the healthcare worker and knowledge score was reported in previous studies (Liu et al., 2018; Mustafa et al., 2018). In our study, the exposure to CHB patients in the past also influenced the score, and those professionals did not show improved results. However, another study noted contradictory results in which workers vaccinated and tested for hepatitis B had higher knowledge scores than those who were unvaccinated (Shrestha et al., 2020). In our study, the workers who had attended HBV training in the last two years had improved scores than others. This highlights the importance of training to enhance knowledge about hep B among healthcare workers.

49% of the respondents in our study were concerned about coming in contact with patients infected with CHB. This stigma among healthcare professionals can cause psychological strain on the patients. Another study also reported the unwillingness of nurses to deal with viral hepatitis patients (Ishimaru et al., 2017). This attitude is also reflected in public individuals who believe in the myth of hep B transmission through sharing food. Encouraging training and education among healthcare workers and the public can be an excellent start to improving knowledge. Our study has some limitations. The study was single-

centered; hence, the results cannot be representative of different regions and hospitals in the country. In addition, the responses were self-reported, so self-bias must be considered.

Conclusion

The awareness and knowledge about hepatitis B prevention and transmission among healthcare workers in Pakistan is poor. Training programs should be mandatory for professionals to improve the management of disease.

Declarations

Data Availability statement

All data generated or analyzed during the study are included in the manuscript. Ethics approval and consent to participate Approved by the department Concerned. Consent for publication Approved Funding

Not applicable

Conflict of interest

The authors declared absence of conflict of interest.

Author Contribution

MUHAMMAD FARHAN JAMIL (Senior Demonstrator)

Manuscript revisions, critical input.

AHMAD MUHAMMAD IMRAN KHAN (Demonstrator) Conception of Study, Development of Research Methodology Design, Study Design,, Review of manuscript, final approval of manuscript

Coordination of collaborative efforts.

NAWAL YOUSAF, SENIOR (Demonstrator) Data entry and Data analysis, drafting article

HAFIZ DANISH ALI KHAN (House Officer)

Data acquisition, analysis. Coordination of collaborative efforts

KHURRAM MALIK (Demonstrator)

Conception of Study, Development of Research Methodology Design, Study Design,, Review of manuscript, final approval of manuscript

SALMAN YOUSAF (Senior Demonstrator)

Coordination of collaborative efforts.

Data acquisition, analysis.

References

Abbas, M., Rafique, S., and Asam, Z.-U.-Z. (2023). Occupational health and safety rights of hospital workers about needle stick injury exposure in Pakistan. *International Journal* of Human Rights in Healthcare.

- Abidi, T. F., Ahsan, S. J., and Fatima, N. (2018). Hepatitis B vaccination coverage and immunization status among health care workers in Punjab and Islamabad, Pakistan. *South Asian Journal of Emergency Medicine* 1, 16-16.
- Akazong, E., Tume, C., Njouom, R., Ayong, L., Fondoh, V., and Kuiate, J.-R. (2020). Knowledge, attitude, and prevalence of hepatitis B virus among healthcare workers: a cross-sectional, hospital-based study in Bamenda Health District, NWR, Cameroon. *BMJ open* **10**.
- Auta, A., Adewuyi, E. O., Kureh, G. T., Onoviran, N., and Adeloye, D. (2018). Hepatitis B vaccination coverage among health-care workers in Africa: a systematic review and meta-analysis. *Vaccine* 36, 4851-4860.
- Basireddy, P., Avileli, S., Beldono, N., and Gundela, S. L. (2018). Evaluation of immune response to hepatitis B vaccine in healthcare workers at a tertiary care hospital. *Indian journal of medical microbiology* 36, 397-400.
- Butt, A. S., and Ahmed, F. (2018). Management of chronic hepatitis B: knowledge and practices of physicians in Pakistan. *Journal of clinical and experimental hepatology* 8, 342-351.
- Childs, L., Roesel, S., and Tohme, R. A. (2018). Status and progress of hepatitis B control through vaccination in the South-East Asia Region, 1992–2015. *Vaccine* **36**, 6-14.
- Gul, F., Savul, S., Aamir, R., Zehra, T., Mujtaba, H., and Sadiq, F. (2022). Knowledge and awareness of Hepatitis B, Hepatitis C, and HIV among pregnant women in Pakistan. *The Journal of Infection in Developing Countries* 16, 1512-1516.
- Ishimaru, T., Wada, K., Hoang, H. T. X., Bui, A. T. M., Nguyen, H. D., Le, H., and Smith, D. R. (2017). Nurses' willingness to care for patients infected with HIV or Hepatitis B/C in Vietnam. *Environmental health and* preventive medicine 22, 1-7.
- Khan, M. A., Khilji, M. F., Rauf, A., Janjua, M. I., and Altintas, K. H. (2019). Hepatitis B and C related knowledge, attitudes and practices of health care workers in Azad Kashmir, Pakistan–A potentially disastrous area.
- Liu, Y., Ma, C., Jia, H., Xu, E., Zhou, Y., Zhang, Z., Lu, L., Rodewald, L., and Hao, L. (2018). Knowledge, attitudes, and practices regarding hepatitis B vaccination among hospital-based doctors and nurses in China: Results of a multi-site survey. *Vaccine* 36, 2307-2313.
- Maqsood, S., Iqbal, S., Zakar, R., Zakar, M. Z., and Fischer, F. (2021). Determinants of overall knowledge and health behaviours in relation to hepatitis B and C among evermarried women in Pakistan: evidence based on Demographic and Health Survey 2017–18. BMC Public Health 21, 2328.
- Maucort-Boulch, D., de Martel, C., Franceschi, S., and Plummer, M. (2018). Fraction and incidence of liver cancer attributable to hepatitis B and C viruses worldwide. *International journal of cancer* 142, 2471-2477.
- Mehmood, S., Raza, H., Abid, F., Saeed, N., Rehman, H. M., Javed, S., and Khan, M. S. (2020). National prevalence rate of hepatitis B and C in Pakistan and its risk factors. *Journal* of *Public Health* 28, 751-764.
- Mursy, S. M.-e. M., and Mohamed, S. O. O. (2019). Knowledge, attitude, and practice towards Hepatitis B infection among nurses and midwives in two maternity hospitals in Khartoum, Sudan. *BMC public health* 19, 1-7.
- Musroor, R., and Saleem, S. (2020). Prevalence and perception of needle stick injury among health care professionals at a tertiary care hospital, Karachi, Pakistan. *American Journal of Infection Control* 48, S31.
- Mustafa, A. S. M., Ahmed, A. S. M., Alamin, T. A. A., Shaheen, M. T. H., Hilali, A. M. M. A., Fadul, M. H. M. A., Abdelsalam, A. A. A., Abdelrahim, M. A. S., and Elsheikh, M. N. M. A. (2018). Knowledge, attitude and

practice of hepatitis (B) among healthcare workers in relation to their vaccination status in Khartoum, Sudan, 2015: a cross-sectional study. *Sudan Journal of Medical Sciences* **13**, 22-32.

- Prüss-Üstün, A., Rapiti, E., and Hutin, Y. (2005). Estimation of the global burden of disease attributable to contaminated sharps injuries among health-care workers. *American journal of industrial medicine* **48**, 482-490.
- Qin, Y.-L., Li, B., Zhou, Y.-S., Zhang, X., Li, L., Song, B., Liu, P., Yuan, Y., Zhao, Z.-P., and Jiao, J. (2018). Prevalence and associated knowledge of hepatitis B infection among healthcare workers in Freetown, Sierra Leone. BMC infectious diseases 18, 1-8.
- Razavi-Shearer, D., Gamkrelidze, I., Nguyen, M. H., Chen, D.-S., Van Damme, P., Abbas, Z., Abdulla, M., Abou Rached, A., Adda, D., and Aho, I. (2018). Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study. *The lancet Gastroenterology & hepatology* 3, 383-403.
- Samo, A. A., Laghari, Z. A., Baig, N. M., and Khoso, G. M. (2021). Prevalence and risk factors associated with hepatitis B and C in Nawabshah, Sindh, Pakistan. *The American journal of tropical medicine and hygiene* **104**, 1101.
- Shao, E. R., Mboya, I. B., Gunda, D. W., Ruhangisa, F. G., Temu, E. M., Nkwama, M. L., Pyuza, J. J., Kilonzo, K. G., Lyamuya, F. S., and Maro, V. P. (2018). Seroprevalence of hepatitis B virus infection and associated factors among healthcare workers in northern Tanzania. *BMC infectious diseases* 18, 1-10.
- Shrestha, D. B., Khadka, M., Khadka, M., Subedi, P., Pokharel, S., and Thapa, B. B. (2020). Hepatitis B vaccination status and knowledge, attitude, and practice regarding Hepatitis B among preclinical medical students of a medical college in Nepal. *PloS one* 15, e0242658.
- Soomar, S. M., Siddiqui, A. R., Azam, S. I., and Shah, M. (2021). Determinants of hepatitis B vaccination status in health care workers of two secondary care hospitals of Sindh, Pakistan: A cross-sectional study. *Human vaccines & immunotherapeutics* 17, 5579-5584.
- Waheed, U., Abdella, Y. E., e Saba, N., Arshad, M., Wazeer, A., Farooq, A., Usman, J., Arshad, A., and Zaheer, H. A. (2019). Evaluation of screening effectiveness of hepatitis B surface antigen and anti-HCV rapid test kits in Pakistan. *Journal of Laboratory Physicians* 11, 369-372.



Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <u>http://creativecommons.org/licen</u> ses/by/4.0/. © The Author(s) 2023